menu
    • menu
    [{"orgOrder":0,"company":"DiNAQOR AG","sponsor":"BioMarin Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2020","type":"Licensing Agreement","leadProduct":"DiNA-001","moa":"MYBPC3","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"DiNAQOR AG","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DiNAQOR AG \/ BioMarin Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"DiNAQOR AG \/ BioMarin Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by DiNAQOR AG

    Menu

    DiNAQOR AG

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            DiNAQOR AG

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            DiNAQOR AG

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DiNA-001

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : IND Enabling

                            Sponsor : BioMarin Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            BioMarin Extends Gene Therapy Leadership with DiNAQOR in a Preclinical Collaboration and License Agreement

                            Details : The license initially covers DiNAQOR's lead program, DiNA-001 for MYBPC3 hypertrophic cardiomyopathy. Additionally, the companies will collaborate on several of DiNAQOR's other pipeline programs.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            May 03, 2020

                            Lead Product(s) : DiNA-001

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : BioMarin Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth